Fusions of the rearrangement during transfection (RET) gene present in 1% to 2% of all non-small cell lung cancer (NSCLC) patients,[1] resulting in constitutive activation of oncogenic signaling pathways, promoting tumor growth and survival. The gene discussed is RET; the disease is neoplasm.